CTLA4 and neoplasm: In experimental tumor models, the nanovaccine was efficient in both prophylactic (1 dose/week starting 3 weeks before tumor grafting) and therapeutic settings (doses at day 2, 4, and 7 post tumor grafting, in combination with an anti-CTLA-4 antibody), where ~60% and ~80% of the animals survived (up to 150 days, likely cured), respectively.